8 completed, 1 withdrawn. 3 Phase 3, 2 Phase 2, 2 Phase 4, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow BOL 303259-X: new trials by email Literature Review of BOL 303259-X trials Research Report on BOL 303259-X
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension Latanoprostene Bunod, Placebo - Ocular Hypertension | Phase 4 | Withdrawn | Bausch & Lomb Incorporated | 2022-05-13 | 2024-03-04 | |
| Nailfold Capillary Blood Flow With Latanoprost Bunod Latanoprost 0.005%, Latanoprost bunod 0.024%, Normal saline 0.9% - Glaucoma, Open-Angle | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 47 | 2019-08-15 | 2021-09-29 |
| Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity Latanoprostene bunod 0.024% QD, Timolol maleate 0.5% BID - OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension | Not applicable | Completed | University of California, San Diego | 70 | 2018-12-03 | 2023-08-29 |
| Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT Latanoprostene bunod - Glaucoma, Ocular Hypertension | Phase 3 | Completed | Bausch & Lomb Incorporated | 130 | 2013-07-05 | 2018-07-26 |
| Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers Latanoprostene bunod - Intraocular Pressure | Phase 1 | Completed | Bausch & Lomb Incorporated | 24 | 2013-07-01 | 2018-05-15 |
| Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension BOL-303259-X, Timolol - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Bausch & Lomb Incorporated | 420 | 2013-01-31 | 2018-11-07 |
| Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension BOL-303259-X, Timolol - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Bausch & Lomb Incorporated | 420 | 2013-01-01 | 2018-11-21 |
| BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension BOL-303259-X, Timolol maleate - Ocular Hypertension, Open Angle Glaucoma | Phase 2 | Completed | Bausch & Lomb Incorporated | 25 | 2012-11-01 | 2018-09-04 |
| Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension BOL-303259-X, Latanoprost - Intraocular Pressure | Phase 2 | Completed | Bausch & Lomb Incorporated | 413 | 2010-12-13 | 2018-07-24 |
Ocular Hypertension (6) · Glaucoma, Open-Angle (5) · Eye Diseases (1) · Glaucoma (1)
Bausch & Lomb Incorporated (7) · Icahn School of Medicine at Mount Sinai (1) · University of California, San Diego (1)
United States (9)
Jason Vittitow (2) · Quintus Ngumah, OD, PhD (2) · Anya Loncaric (1) · Jason L. Vittitow, PhD (1) · Rabia Ozden, MD (1) · Robert Ritch, MD (1) · Robert Weinreb, MD (1)
PMID 29194198, PMID 25488946, PMID 26563323, PMID 26875002, PMID 27210275, PMID 27457257, PMID 27457469